Skip to content

Study · Animal study (in vivo) · rat · 2016

10 results

Cerebrolysin dose-dependently improves neurological outcome in rats after acute stroke: A prospective, randomized, blinded, and placebo-controlled study.

Zhang L, Chopp M, Lu M, Zhang T, Winter S, Doppler E, Meier D, Chao L, Eapen A, Pabla P, Gang Zhang Z

International journal of stroke : official journal of the International Stroke Society12 Jan 2016Cited by 20 (Europe PMC)

PMID26763925 (opens in a new tab)DOI10.1177/1747493015625645 (opens in a new tab)PepBankPUB-26763925
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with ischemic stroke, Cerebrolysin had a significant dose effect on neurological outcome.

    In plain wordsIn rats with ischemic stroke, neurological outcome differed significantly by Cerebrolysin dose.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableDose effect on neurological outcome
    Study

    ratn: not reported in source

    Embolic middle cerebral artery occlusion in Wistar rats
    Comparator
    Different Cerebrolysin doses
    Analysis
    Primary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 10 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    There was a significant (p < 0.001) dose effect of Cerebrolysin on neurological outcome.
    3 context sentences
    Summary · context
    The primary outcome was neurologic improvement at day 28, lesion volume, mortality, and animal weight were secondary and safety outcomes, respectively.
    Summary · context
    This study was a prospective, blinded, placebo-controlled, preclinical experiment.
    Summary · context
    Male and female Wistar rats, subjected to embolic middle cerebral artery occlusion, were randomly treated with Cerebrolysin doses of 0.8, 2.5, 5.0, 7.5 ml/kg or placebo, 4 h after middle cerebral artery occlusion for a total of 10 consecutive days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with ischemic stroke, Cerebrolysin 0.8 ml/kg did not significantly improve neurological outcome at day 28 versus placebo.

    In plain wordsIn rats with ischemic stroke, Cerebrolysin 0.8 ml/kg did not significantly improve neurological outcome at day 28 compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeNeurological outcome at 0.8 ml/kg
    Study

    ratn: not reported in source

    Embolic middle cerebral artery occlusion in Wistar rats
    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    0.8 ml/kg · 10 consecutive daysAs given in this study (rat).

    Measurements

    Mean Estimate
    6.2
    0.8 ml/kg
    95% CL lower
    −6
    0.8 ml/kg
    95% CL upper
    18.4
    0.8 ml/kg

    Source sentences

    Summary
    Cerebrolysin at a dose of ≥ 2.5 ml/kg significantly (p < 0.001) improved neurological outcome (Mean Estimate (95% CL): 0.8 ml/kg: 6.2 (-6.0/18.4), 2.5 ml/kg: -28.9 (-41.6/-16.2), 5.0 ml/kg: -33.4 (-45.0/-21.7), 7.5 ml/kg: -36.3 (-48.2/-24.4).
    3 context sentences
    Summary · context
    The primary outcome was neurologic improvement at day 28, lesion volume, mortality, and animal weight were secondary and safety outcomes, respectively.
    Summary · context
    This study was a prospective, blinded, placebo-controlled, preclinical experiment.
    Summary · context
    Male and female Wistar rats, subjected to embolic middle cerebral artery occlusion, were randomly treated with Cerebrolysin doses of 0.8, 2.5, 5.0, 7.5 ml/kg or placebo, 4 h after middle cerebral artery occlusion for a total of 10 consecutive days.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with ischemic stroke, Cerebrolysin 2.5 ml/kg improved neurological outcome at day 28 versus placebo.

    In plain wordsIn rats with ischemic stroke, Cerebrolysin 2.5 ml/kg improved neurological outcome at day 28 compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNeurological outcome at 2.5 ml/kg
    Study

    ratn: not reported in source

    Embolic middle cerebral artery occlusion in Wistar rats
    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5 ml/kg · 10 consecutive daysAs given in this study (rat).

    Measurements

    Mean Estimate
    −28.9
    2.5 ml/kg
    95% CL lower
    −41.6
    2.5 ml/kg
    95% CL upper
    −16.2
    2.5 ml/kg

    Source sentences

    Summary
    Cerebrolysin at a dose of ≥ 2.5 ml/kg significantly (p < 0.001) improved neurological outcome (Mean Estimate (95% CL): 0.8 ml/kg: 6.2 (-6.0/18.4), 2.5 ml/kg: -28.9 (-41.6/-16.2), 5.0 ml/kg: -33.4 (-45.0/-21.7), 7.5 ml/kg: -36.3 (-48.2/-24.4).
    3 context sentences
    Summary · context
    The primary outcome was neurologic improvement at day 28, lesion volume, mortality, and animal weight were secondary and safety outcomes, respectively.
    Summary · context
    This study was a prospective, blinded, placebo-controlled, preclinical experiment.
    Summary · context
    Male and female Wistar rats, subjected to embolic middle cerebral artery occlusion, were randomly treated with Cerebrolysin doses of 0.8, 2.5, 5.0, 7.5 ml/kg or placebo, 4 h after middle cerebral artery occlusion for a total of 10 consecutive days.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with ischemic stroke, Cerebrolysin 5.0 ml/kg improved neurological outcome at day 28 versus placebo.

    In plain wordsIn rats with ischemic stroke, Cerebrolysin 5.0 ml/kg improved neurological outcome at day 28 compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNeurological outcome at 5.0 ml/kg
    Study

    ratn: not reported in source

    Embolic middle cerebral artery occlusion in Wistar rats
    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5.0 ml/kg · 10 consecutive daysAs given in this study (rat).

    Measurements

    Mean Estimate
    −33.4
    5.0 ml/kg
    95% CL lower
    −45
    5.0 ml/kg
    95% CL upper
    −21.7
    5.0 ml/kg

    Source sentences

    Summary
    Cerebrolysin at a dose of ≥ 2.5 ml/kg significantly (p < 0.001) improved neurological outcome (Mean Estimate (95% CL): 0.8 ml/kg: 6.2 (-6.0/18.4), 2.5 ml/kg: -28.9 (-41.6/-16.2), 5.0 ml/kg: -33.4 (-45.0/-21.7), 7.5 ml/kg: -36.3 (-48.2/-24.4).
    3 context sentences
    Summary · context
    The primary outcome was neurologic improvement at day 28, lesion volume, mortality, and animal weight were secondary and safety outcomes, respectively.
    Summary · context
    This study was a prospective, blinded, placebo-controlled, preclinical experiment.
    Summary · context
    Male and female Wistar rats, subjected to embolic middle cerebral artery occlusion, were randomly treated with Cerebrolysin doses of 0.8, 2.5, 5.0, 7.5 ml/kg or placebo, 4 h after middle cerebral artery occlusion for a total of 10 consecutive days.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with ischemic stroke, Cerebrolysin 7.5 ml/kg improved neurological outcome at day 28 versus placebo.

    In plain wordsIn rats with ischemic stroke, Cerebrolysin 7.5 ml/kg improved neurological outcome at day 28 compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNeurological outcome at 7.5 ml/kg
    Study

    ratn: not reported in source

    Embolic middle cerebral artery occlusion in Wistar rats
    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    7.5 ml/kg · 10 consecutive daysAs given in this study (rat).

    Measurements

    Mean Estimate
    −36.3
    7.5 ml/kg
    95% CL lower
    −48.2
    7.5 ml/kg
    95% CL upper
    −24.4
    7.5 ml/kg

    Source sentences

    Summary
    Cerebrolysin at a dose of ≥ 2.5 ml/kg significantly (p < 0.001) improved neurological outcome (Mean Estimate (95% CL): 0.8 ml/kg: 6.2 (-6.0/18.4), 2.5 ml/kg: -28.9 (-41.6/-16.2), 5.0 ml/kg: -33.4 (-45.0/-21.7), 7.5 ml/kg: -36.3 (-48.2/-24.4).
    3 context sentences
    Summary · context
    The primary outcome was neurologic improvement at day 28, lesion volume, mortality, and animal weight were secondary and safety outcomes, respectively.
    Summary · context
    This study was a prospective, blinded, placebo-controlled, preclinical experiment.
    Summary · context
    Male and female Wistar rats, subjected to embolic middle cerebral artery occlusion, were randomly treated with Cerebrolysin doses of 0.8, 2.5, 5.0, 7.5 ml/kg or placebo, 4 h after middle cerebral artery occlusion for a total of 10 consecutive days.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with ischemic stroke, Cerebrolysin 5 ml/kg reduced lesion volume versus placebo.

    In plain wordsIn rats with ischemic stroke, Cerebrolysin 5 ml/kg reduced brain lesion volume compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseLesion volume
    Study

    ratn: not reported in source

    Embolic middle cerebral artery occlusion in Wistar rats
    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 ml/kg · 10 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    Treatment with 5 ml/kg reduced lesion volume (p = 0.016).
    3 context sentences
    Summary · context
    The primary outcome was neurologic improvement at day 28, lesion volume, mortality, and animal weight were secondary and safety outcomes, respectively.
    Summary · context
    This study was a prospective, blinded, placebo-controlled, preclinical experiment.
    Summary · context
    Male and female Wistar rats, subjected to embolic middle cerebral artery occlusion, were randomly treated with Cerebrolysin doses of 0.8, 2.5, 5.0, 7.5 ml/kg or placebo, 4 h after middle cerebral artery occlusion for a total of 10 consecutive days.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with ischemic stroke, recovery did not differ significantly between effective Cerebrolysin doses of ≥ 2.5 ml/kg.

    In plain wordsIn rats with ischemic stroke, recovery did not differ significantly between effective Cerebrolysin doses of ≥ 2.5 ml/kg.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeRecovery differences between effective doses
    Study

    ratn: not reported in source

    Embolic middle cerebral artery occlusion in Wistar rats
    Comparator
    Other effective Cerebrolysin doses
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    ≥ 2.5 ml/kg · 10 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    Higher doses (≥ 2.5 ml/kg) resulted in better recovery; however, differences between effective doses were not significant.
    2 context sentences
    Summary · context
    This study was a prospective, blinded, placebo-controlled, preclinical experiment.
    Summary · context
    Male and female Wistar rats, subjected to embolic middle cerebral artery occlusion, were randomly treated with Cerebrolysin doses of 0.8, 2.5, 5.0, 7.5 ml/kg or placebo, 4 h after middle cerebral artery occlusion for a total of 10 consecutive days.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with ischemic stroke, Cerebrolysin showed no treatment gender interactions.

    In plain wordsIn rats with ischemic stroke, Cerebrolysin treatment effects did not differ by sex.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeTreatment gender interaction
    Study

    ratn: not reported in source

    Embolic middle cerebral artery occlusion in Wistar rats
    Comparator
    Male versus female treatment response
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 10 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    No treatment gender interactions were found and there were no differences in death or weight loss.
    2 context sentences
    Summary · context
    This study was a prospective, blinded, placebo-controlled, preclinical experiment.
    Summary · context
    Male and female Wistar rats, subjected to embolic middle cerebral artery occlusion, were randomly treated with Cerebrolysin doses of 0.8, 2.5, 5.0, 7.5 ml/kg or placebo, 4 h after middle cerebral artery occlusion for a total of 10 consecutive days.
  9. 09AnimalAnimal study (in vivo)Safety outcome

    In rats with ischemic stroke, death did not differ between Cerebrolysin and placebo treatment groups.

    In plain wordsIn rats with ischemic stroke, deaths did not differ between Cerebrolysin and placebo groups.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeDeath
    Study

    ratn: not reported in source

    Embolic middle cerebral artery occlusion in Wistar rats
    Comparator
    Placebo
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated · 10 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    No treatment gender interactions were found and there were no differences in death or weight loss.
    2 context sentences
    Summary · context
    This study was a prospective, blinded, placebo-controlled, preclinical experiment.
    Summary · context
    Male and female Wistar rats, subjected to embolic middle cerebral artery occlusion, were randomly treated with Cerebrolysin doses of 0.8, 2.5, 5.0, 7.5 ml/kg or placebo, 4 h after middle cerebral artery occlusion for a total of 10 consecutive days.
  10. 10AnimalAnimal study (in vivo)Safety outcome

    In rats with ischemic stroke, weight loss did not differ between Cerebrolysin and placebo treatment groups.

    In plain wordsIn rats with ischemic stroke, weight loss did not differ between Cerebrolysin and placebo groups.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeWeight loss
    Study

    ratn: not reported in source

    Embolic middle cerebral artery occlusion in Wistar rats
    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 10 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    No treatment gender interactions were found and there were no differences in death or weight loss.
    2 context sentences
    Summary · context
    This study was a prospective, blinded, placebo-controlled, preclinical experiment.
    Summary · context
    Male and female Wistar rats, subjected to embolic middle cerebral artery occlusion, were randomly treated with Cerebrolysin doses of 0.8, 2.5, 5.0, 7.5 ml/kg or placebo, 4 h after middle cerebral artery occlusion for a total of 10 consecutive days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.